| Name | Title | Contact Details |
|---|
Enclara Pharmacia is the combination resulting from the August 2014 acquisition of Hospice Pharmacia by Enclara Health. We believe that this marriage creates the only true solution for hospice mail order pharmacy services and augments an already robust PBM local offering for hospices that want a choice in their pharmacy service model. Andy Horowitz, CEO, continues to lead Enclara Pharmacia. Enclara Pharmacia serves over 500 hospice providers and 84,000 hospice patients per day nationwide. Enclara’s mail order model provides comprehensive pharmacy support, delivering medications directly to hospice patients’ homes, with the backup of local pharmacies to serve their same-day and emergency needs. Comprehensive services include pharmacist consultation 24/7, patient Drug Utilization Review (DUR), Conditions of Participation (CoP) reports, formulary management, account management, and online reporting—all bundled into a predictable per diem reimbursement model. Enclara Pharmacia’s PBM Plus offering provides you with abundant choice and access to our powerful local pharmacy network contracting platform. The service is offered at a fee for service (FFS) price, unbundled, allowing you to choose the level of clinical intervention, if any, your hospice requires, and to “pay as you go” as those resources are utilized. The program gives the control back to you, supporting overall cost containment.
Maker of high quality and affordable generic pharmaceutical products
Dedicated to Global Product Safety, Brand Loyalty, and Patient Access Strategies that Support the Full Product Lifecycle United BioSource LLC (UBC) is a leading provider of pharmaceutical support services, partnering with life science companies to make medicine and medical products safer and more accessible. Our diverse suite of services helps bridge the gap between development and delivery and builds brand loyalty through patient access and adherence. UBC is well known for our ability to generate authoritative, real-world evidence of product effectiveness, safety, and value to assist healthcare decisions and enhance patient care. Developing a drug, taking it through commercialization, and demonstrating its post-launch value and safety is a complex journey. Regulatory hurdles and payer decision-making are increasing the complexity around drug development and product choices. UBC has aligned our expertise and industry insight to help manufacturers make informed decisions early in the product journey that ultimately optimize care and improve patient outcomes. The most successful product journeys start with great maps. UBC`s industry-leading experts work in unison to effectively navigate the product lifecycle, focusing on: Clinical Development Safety Commercialization We understand what it takes to compete in a crowded product market with many stakeholders that demand the right evidence at the right time. Our Past, Present, and Our Future UBC was founded in 2003 by industry experts with a passion for innovation and a commitment to working with pharmaceutical and biotech organizations in proving the safety, efficacy, and value of pharmaceutical and medical products. We recognized the opportunity to build an organization tailored to meet the need for scientific evidence in the healthcare industry. And, we quickly developed our core strength – the generation, analysis, and communication of real-world evidence throughout the product lifecycle.
ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.
Janssen Alzheimer Immunotherapy div JNJ is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.